Sugi Predict

Sugi Predict / Compounds / SCHEMBL6942386

SCHEMBL6942386

SCHEMBL6942386

Nc1nccn2c(C3CCN(C(=O)c4ccsc4)CC3)nc(-c3cc4cccc(-c5ccccc5)c4[nH]3)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 1/20 0.57
▸ PIK3CB P42338 1/20 0.57
▸ MTOR P42345 1/20 0.57
▸ PIK3CG P48736 1/20 0.57
▸ PRKDC P78527 1/20 0.57
▸ RICTOR Q6R327 1/20 0.57
▸ RPTOR Q8N122 1/20 0.57
▸ MAPKAP1 Q9BPZ7 1/20 0.57
▸ MLST8 Q9BVC4 1/20 0.57
▸ RAF1 P04049 2/20 0.55
▸ SRC P12931 2/20 0.55
▸ IGF1R P08069 4/20 0.48
▸ PDPK1 O15530 1/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ EGFR P00533 1/20 0.48
▸ INSR P06213 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ MAP2K1 Q02750 1/20 0.48
▸ TNK2 Q07912 13/20 0.47
▸ FGFR1 P11362 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6942933 0.90 PIK3CA (0.57) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL6941913 0.90 PIK3CA (0.57) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL6942932 0.90 PIK3CA (0.59) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL6942739 0.90 PIK3CA (0.57) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL6940860 0.89 PIK3CA (0.56) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL595244 0.88 RAF1 (0.71) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL15925806 0.88 MTOR (0.55) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL6939097 0.87 PIK3CA (0.54) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL6942234 0.84 RAF1 (0.77) PIK3CAPIK3CBMTORPIK3CGPRKDC
SCHEMBL11980649 0.84 PIK3CA (0.61) PIK3CAPIK3CBMTORPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796455-B2 Fused bicyclic mTOR inhibitors OSI Pharmaceuticals, LLC (US) 2014-08-05 — — US disclosed
US-8796455-B2 Fused bicyclic mTOR inhibitors OSI Pharmaceuticals, LLC (US) 2014-08-05 — — US disclosed
US-8586546-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-11-19 — — US disclosed
EP-2385053-B1 Intermediates for the preparation of fused bicyclic mTOR inhibitors OSI PHARM INC (US) 2013-10-02 — — EP disclosed
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS OSI Pharmaceuticals, LLC 2013-06-27 — — US disclosed
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS OSI Pharmaceuticals, LLC 2013-06-27 — — US disclosed
US-8314111-B2 Fused bicyclic motor inhibitors OSI Pharmaceuticals, LLC (US) 2012-11-20 — — US disclosed
US-8314111-B2 Fused bicyclic motor inhibitors OSI Pharmaceuticals, LLC (US) 2012-11-20 — — US disclosed
US-20120207767-A1 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors OSI PHARMACEUTICALS, LLC. 2012-08-16 — — US disclosed
US-20120207767-A1 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors OSI PHARMACEUTICALS, LLC. 2012-08-16 — — US disclosed
US-7651687-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-26 — — US disclosed
US-7651687-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-26 — — US disclosed
US-20090274698-A1 Combination anti-cancer therapy OSI PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090274698-A1 Combination anti-cancer therapy OSI PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163468-A1 Fused Bicyclic mTor Inhibitors MTOR, RICTOR, MAPKAP1 PIK3CA 25/4885PIK3CB 92/4885MTOR 1/4885
US-20120207767-A1 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors EGFR, ERBB2, MTOR PIK3CA 14/4885PIK3CB 109/4885MTOR 3/4885
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS MTOR, RICTOR, MAPKAP1 PIK3CA 25/4885PIK3CB 92/4885MTOR 1/4885
US-20090274698-A1 Combination anti-cancer therapy MTOR, RICTOR, AKT1 PIK3CA 10/4885PIK3CB 26/4885MTOR 1/4885
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors EGFR, ERBB2, RICTOR PIK3CA 57/4885PIK3CB 350/4885MTOR 5/4885
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer MTOR, MAPKAP1, RPS6KA1 PIK3CA 90/4885PIK3CB 144/4885MTOR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.